Eleusis Therapeutics US Inc. has synthesized aryl-ring-substituted 3-phenylazetidines acting as 5-HT2 receptor ligands reported to be useful for the treatment of chronic pain, depression, atherosclerosis, chronic obstructive pulmonary disease, conjunctivitis, type 2 diabetes, multiple sclerosis and rheumatoid arthritis, among others.
Sensorium Therapeutics Inc. closed a $30 million series A round to fund the discovery and development of new psychiatric drugs, inspired by human ethnobotanical practices that date back hundreds or even thousands of years.
Sunovion Pharmaceuticals Inc. has identified chroman and benzofuran derivatives acting as 5-HT1A and trace amine-associated receptor 1 (TAAR1) agonists reported to be useful for the treatment of depression.
Researchers in China have discovered a new therapeutic target, and identified a rapid-acting lead compound that may overcome the drawbacks of current antidepressants. The research team, based at Nanjing Medical University’s School of Pharmacy, designed a fast-acting antidepressant that works by disrupting the interaction between the serotonin transporter (SERT) and neuronal nitric oxide synthase (nNOS) in the dorsal raphe nucleus. The dorsal raphe nucleus (DRN) of the midbrain influences a number of central nervous system processes, and the main transmitter of the DRN is serotonin, the primary target for most antidepressants. Neurons communicate with each other by releasing a series of neurotransmitters into the synaptic space, and these transmitted electrical signals ultimately determine feelings, thoughts and actions, explained co-lead study author Qi-Gang Zhou. The study was published in Science on Oct. 28, 2022.
The potential for psychedelics to deliver long-lasting benefits for people with anxiety, depression, post-traumatic stress disorder and addiction is being put to the test in Australia, where new research and discovery centers are adding to a global enterprise of nearly 100 clinical trials underway in the space.
The potential for psychedelics to deliver long-lasting benefits for people with anxiety, depression, post-traumatic stress disorder and addiction is being put to the test in Australia, where new research and discovery centers are adding to a global enterprise of nearly 100 clinical trials underway in the space.
Vanderbilt University has patented metabotropic glutamate receptor subtype 2 (mGluR2) negative allosteric modulators reported to be useful for the treatment of depression, anxiety, Alzheimer's disease, obsessive-compulsive and autism spectrum disorders.
There is little doubt that progress in many brain diseases is being hampered because many, maybe most, diagnostic categories do not reflect underlying brain processes. In other disease areas, modern genetic and genomic methods have arrived in the form of approved drugs, from KRAS inhibitors in cancer to PCSK9 inhibitors to lower cholesterol. But brain diseases are different. Psychiatry is simultaneously the most personal area of medicine, and the least precise.